CAR T-Cell Therapy: Revolutionizing Cancer Treatment

September 30, 2020

Ready your research for success with expert insight from TD2 on how to launch a successful CAR-T trial. Learn the key areas to take into account when beginning this type of oncology trial to ensure proper trial preclinical study design, uncover efficiencies and identify toxicity.

Model Spotlight: Breast Cancer Clinical Update and Preclinical Plan

Based on the American Cancer Society 2026 estimates and survival statistics, as of October 2026, developments in antibody-drug conjugates (ADCs), ...

Read more +

Advancing Preclinical Research in Gynecologic Cancers

Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...

Read more +

History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies

CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.